trusted by 100+ Patients

RGCC aCGH Test

Advanced Genetic Profiling for Cancer Detection and Treatment Optimization

Treatment Intro

What is RGCC aCGH Test?

The RGCC aCGH Test (array Comparative Genomic Hybridization) is a state-of-the-art genetic test designed to detect genetic abnormalities associated with cancer. 

It provides a detailed analysis of the entire genome, helping to identify chromosomal imbalances such as gains or losses of genetic material, which can play a crucial role in cancer development. This test offers essential insights into the genetic profile of cancer cells, aiding in the early detection of cancer, personalized treatment planning, and monitoring cancer progression or recurrence.

Why to Choose it

Why Choose RGCC aCGH Test?

Gain a comprehensive view of your genetic profile - the RGCC aCGH Test detects chromosomal changes linked to cancer, helping guide personalised treatment decisions and improve long-term outcomes.
🌿

Advanced Genetic Profiling

The RGCC aCGH test provides a comprehensive and in-depth look at the genetic makeup of cancer cells, allowing for early identification of genetic abnormalities.
🦠

Personalized Cancer Treatment

By identifying specific genetic alterations in cancer cells, this test enables healthcare providers to design personalized treatment plans that target the unique genetic profile of your cancer, increasing the likelihood of successful outcomes.
🛡️

Early Detection of Cancer

The test can identify genetic changes associated with cancer at its earliest stages, allowing for more timely and effective intervention.
🧠

Non-Invasive and Accurate

The test only requires a blood or tissue sample, making it a safe, non-invasive method to assess your genetic risk and the presence of cancer.
⚖️

Ongoing Monitoring

The RGCC aCGH Test is also useful for monitoring the genetic changes in cancer over time, helping to track the effectiveness of treatment and detect potential relapses.

The Process

How Does RGCC aCGH Test Work?

The RGCC aCGH Test uses advanced genomic technology to analyze a patient’s DNA for any genetic imbalances. It works by comparing the DNA sample from the cancer cells to a reference genome to identify any chromosomal abnormalities, such as:
Book a consultation
01
Chromosomal Gains
Areas of the genome where additional copies of genes are present, which can lead to the overproduction of proteins and contribute to cancer development.
02
Chromosomal Losses
Areas where parts of the genetic material are missing, which can result in the loss of tumor suppressor genes that help control cell growth.
03
Gene Amplifications
When specific genes are copied multiple times, leading to abnormal cell growth and tumor development.

Perfect for

Is This Test Right for You?

Who Can Benefit from RGCC aCGH Test?
Cancer Patients: It can help identify specific genetic alterations driving the growth of the tumor. This allows healthcare providers to choose targeted therapies that address the genetic basis of your cancer.
Cancer Survivors: For those in remission, the test can help monitor for any genetic changes that might signal a recurrence, enabling early intervention.
People at High Risk of Cancer: If you have a family history of cancer or carry genetic mutations that increase your risk, it can help detect early genetic changes that might indicate the development of cancer.
Individuals Seeking Personalized Medicine : If you want a treatment plan tailored specifically to the genetic profile of your cancer, the RGCC aCGH Test is an invaluable tool in selecting the most effective therapies.
Monitoring Cancer Treatment Effectivness: The test allows healthcare providers to track how genetic changes in the tumor respond to treatment, enabling the adjustment of therapies for optimal results.

FAQs

01

What is the RGCC aCGH Test used for?

The RGCC aCGH Test (array Comparative Genomic Hybridisation) is a type of genetic cancer testing used to detect chromosomal abnormalities linked to cancer. It helps healthcare providers understand the genetic changes present in tumor cells, which can guide more precise and personalised cancer treatment.

02

Who should consider taking this test?

This test is beneficial for:

- Individuals already diagnosed with cancer, who want to understand the genetic basis of their disease.

- Patients with an increased cancer risk due to family history or known gene mutations

- Survivors seeking early detection of potential recurrence.

- People at high risk due to cancer genetic susceptibility syndromes or hereditary cancer traits.

03

Can this test be used to assess inherited cancer risk?

The RGCC aCGH Test is primarily designed to detect somatic (tumour-acquired) chromosomal abnormalities, not inherited mutations. While some findings may suggest patterns associated with inherited cancer syndromes, it is not intended as a first-line tool for evaluating hereditary risk. Individuals with cancer family members, especially those diagnosed at a young age or with rare cancers, should undergo dedicated germline genetic testing. A genetic counsellor can help interpret any results and recommend whether further evaluation is needed.

04

What is the testing process?

To perform the RGCC aCGH Test, a blood sample or tumour tissue biopsy is collected, depending on the clinical indication. The sample is then analysed in a specialised laboratory using array Comparative Genomic Hybridisation (aCGH) technology to assess the entire genome for chromosomal imbalances. The process is typically straightforward and minimally invasive, with blood samples being the least invasive option. Your healthcare provider will determine the most suitable sample type based on your condition.

05

What types of genetic changes does the test detect?

The RGCC aCGH Test identifies key chromosomal abnormalities, including:

- Gains and losses of genetic material (copy number variations)

- Gene amplifications that may contribute to tumour growth and progression
These results give critical insights into the molecular mechanisms driving human cancer and help doctors personalise treatment.

06

Does the test detect inherited mutations?

It may reveal inherited or acquired abnormalities, but for a full evaluation of inherited cancer risk, additional genetic counseling and specific germline testing may be recommended. A trained genetic counselor can help interpret results and assess whether further medical tests are necessary.

07

Is this test suitable for people of all backgrounds?

Yes. Certain racial or ethnic groups may carry higher rates of specific genes tested in oncology, making genetic insights particularly valuable in assessing cancer risk factors and planning treatment.

08

What happens after I receive my genetic test results?

Your genetic test results will be reviewed by your doctor, who may adjust your treatment strategy based on the genetic profile of your cancer. If relevant, you may also be referred to a genetic counselor for further discussion and clarification regarding your inherited cancer risk or implications for family members.

09

Is this test used in clinical oncology today?

Yes. The RGCC aCGH Test is part of a growing movement in clinical oncology towards personalised, genomics-driven care. It helps inform targeted therapies and allows ongoing monitoring as the genetic profile of the tumour evolves.

10

Can this test help detect cancer early?

The RGCC aCGH Test may assist in identifying chromosomal abnormalities at an early stage in individuals with an increased risk of cancer, such as those with inherited cancer syndromes or a strong family history. It can support earlier intervention by detecting genomic changes in known tumours or high-risk cases before symptoms appear.

11

What does a negative test result mean?

A negative test result from the RGCC aCGH Test means no significant chromosomal abnormalities were detected based on the sensitivity of the technology. However, it does not completely rule out the presence of smaller genetic changes, such as point mutations, or inherited cancer syndromes. Further genetic evaluation may still be appropriate depending on personal or family history.

12

Will I need follow-up testing after receiving my results?

If the RGCC aCGH Test (array CGH) detects significant chromosomal abnormalities or suggests inherited risk, your doctor may recommend follow-up testing. This could include more targeted genetic tests to confirm the findings, additional screening tests to monitor for early signs of cancer, or further evaluation to assess potential risks for other family members.